What smart money is saying about AbCellera Biologics
1 fund in our archive has pitched AbCellera Biologics — most recently Acatis in September 2026.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Get an email when a fund writes about it
Position history
Every position in AbCellera Biologics on record in the archive was reported in Q3 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 1 |
Fund activity · 1 position
- HoldsAcatisSeptember 2026
“Mr. Leber, the ACATIS Datini Valueflex Fonds gained almost nine percent in August. Was it due to the Bitcoin re- covery? Yes, but it was not the only reason.The portfo- lio contains more than 80 individual positions, of which 15 gained more than 21 percent in August. I like to compare it to a collection of springs - you never know which one will shoot up, and when. In August, it was the (mostly smaller) biotech companies - they contribu- ted more to the monthly performance than our crypto investments. The biggest ‚jumper‘ in this sense was AbCellera Biologics.”
AbCellera Biologics
Fund coverage · 1 thesis
- AcatisSeptember 2026
AbCellera Biologics is an antibody-discovery company that gained on positive Phase 2 data for a menopause treatment.
Read the full thesis
Read every full thesis on AbCellera Biologics
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→